Literature DB >> 3182580

Comparative studies on interaction between theophylline and quinolones.

K Takagi1, T Hasegawa, Y Ogura, R Suzuki, K Yamaki, T Watanabe, S Kitazawa, T Satake.   

Abstract

A comparative study of the pharmacokinetic and metabolic interactions between theophylline and a newly developed quinolone, T-3262, was carried out under steady-state conditions in seven healthy male volunteers, using enoxacin as the reference drug. A sustained-release theophylline formulation (200 mg twice daily) was given as monotherapy and coadministered with T-3262 (150 mg three times a day) or enoxacin (200 mg three times a day). The total and free concentrations of theophylline in the plasma and the excreted concentration of theophylline and its metabolites in the urine were measured by a high-performance liquid chromatography method. The mean steady-state plasma theophylline concentration significantly increased by approximately 1.5-fold and threefold after coadministration of T-3262 and enoxacin, respectively. In both cases, a significant decrease in the total body clearance was found for T-3262 (34%) and enoxacin (63%), but the plasma protein binding of theophylline remained unchanged. There was a significant increase in urinary theophylline and a decrease in urinary 3-methylxanthine after coadministration of T-3262 or enoxacin. The degree of change in the steady-state plasma theophylline concentration as a result of coadministration of T-3262 was small compared to that of enoxacin. A decrease in the total body clearance in the case of coadministration of a quinolone probably resulted from inhibition of the 1-demethylation metabolic pathway.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3182580     DOI: 10.3109/02770908809071356

Source DB:  PubMed          Journal:  J Asthma        ISSN: 0277-0903            Impact factor:   2.515


  9 in total

1.  Effects of 2 quinolone antibacterials, temafloxacin and enoxacin, on theophylline pharmacokinetics.

Authors:  F Sörgel; G Mahr; G R Granneman; U Stephan; P Nickel; P Muth
Journal:  Clin Pharmacokinet       Date:  1992       Impact factor: 6.447

Review 2.  Pharmacokinetic interactions between theophylline and other medication (Part II).

Authors:  R A Upton
Journal:  Clin Pharmacokinet       Date:  1991-02       Impact factor: 6.447

3.  Quantitative Prediction of Drug Interactions Caused by CYP1A2 Inhibitors and Inducers.

Authors:  Laurence Gabriel; Michel Tod; Sylvain Goutelle
Journal:  Clin Pharmacokinet       Date:  2016-08       Impact factor: 6.447

4.  Influence of a newly developed quinolone, T-3761, on pharmacokinetics of theophylline in rats.

Authors:  T Hasegawa; M Nadai; S Haghgoo; K Yamaki; K Takagi; T Nabeshima
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

5.  Absence of effect of rufloxacin on theophylline pharmacokinetics in steady state.

Authors:  M Kinzig-Schippers; U Fuhr; M Cesana; C Müller; A H Staib; S Rietbrock; F Sörgel
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

Review 6.  Clinically significant pharmacokinetic interactions between dietary caffeine and medications.

Authors:  J A Carrillo; J Benitez
Journal:  Clin Pharmacokinet       Date:  2000-08       Impact factor: 6.447

Review 7.  Clinical pharmacokinetics of ciprofloxacin.

Authors:  K Vance-Bryan; D R Guay; J C Rotschafer
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

8.  Effects of enoxacin on renal and metabolic clearance of theophylline in rats.

Authors:  M Nadai; T Hasegawa; T Kuzuya; I Muraoka; K Takagi; H Yoshizumi
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

9.  Effect of a new quinolone, sparfloxacin, on the pharmacokinetics of theophylline in asthmatic patients.

Authors:  K Takagi; K Yamaki; M Nadai; T Kuzuya; T Hasegawa
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.